Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Public ClinicalTrials.gov record NCT01325701. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Study identification
- NCT ID
- NCT01325701
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Enrollment
- 78 participants
Conditions and interventions
Conditions
Interventions
- ibrutinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2011
- Primary completion
- Sep 30, 2014
- Completion
- Sep 30, 2014
- Last update posted
- Mar 30, 2017
2011 – 2014
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Medical Center | Los Angeles | California | 90095 | — |
| Stanford University School of Medicine | Stanford | California | 94305 | — |
| National Cancer Institute | Bethesda | Maryland | 20892-1203 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Long Island Jewish Medical Center | New Hyde Park | New York | 11042 | — |
| New York University | New York | New York | 10016 | — |
| Weill Medical College of Cornell University | New York | New York | 10021 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| University of Rochester School of Medicine and Dentistry | Rochester | New York | 14642 | — |
| The Ohio Sate university | Columbus | Ohio | 43210 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Univerity of Washington | Seattle | Washington | 98109 | — |
| University of Wisconsin | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01325701, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 30, 2017 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01325701 live on ClinicalTrials.gov.